Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Pyxis Oncology (PYXS) Invested Capital (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Invested Capital for 2 consecutive years, with $68.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 55.25% to $68.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $68.8 million, a 55.25% decrease, with the full-year FY2024 number at $120.8 million, changed N/A from a year prior.
  • Invested Capital was $68.8 million for Q3 2025 at Pyxis Oncology, down from $87.6 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $184.2 million in Q1 2024 to a low of $68.8 million in Q3 2025.